US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Merck & Co., Inc.

MRKNYSE

94.64

USD
+0.81
(+0.86%)
After Hours Market
16.82P/E
13Forward P/E
0.65P/E to S&P500
239.327BMarket CAP
2.81%Div Yield
Upcoming Earnings
28 Jul
Shares Short
4/29/22
16.98M
Short % of Float
0.67%
Short % of Shares Outs.
0.67%
% Held by Insiders
0.10%
% Held by Institutions
75.15%
Beta
0.46
PEG Ratio
1.10
52w. high/low
94.92/70.89
Avg. Daily Volume
11.65M
Return %
Stock
S&P 500
1 year
23.00
(6.45)
3 years
21.34
38.29
5 years
52.49
62.74
Scale: |
High
Low
58.80
40.41
58.38
21.77
36.66
19.13
39.66
29.29
36.16
28.12
45.80
35.22
48.11
38.96
59.35
47.04
60.71
43.60
62.46
45.77
63.74
51.17
76.52
50.41
88.40
68.75
87.92
62.26
91.40
68.44
94.56
72.88
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
Revenue per share
10.39
11.15
11.17
13.01
14.86
15.80
15.62
15.04
14.88
14.20
14.48
14.88
16.31
18.45
18.97
19.25
Earnings per share
2.04
1.51
3.66
6.12
0.28
2.06
2.04
1.50
4.20
1.60
1.43
0.89
2.40
3.88
2.79
5.16
FCF per share
2.66
2.76
2.47
0.92
2.95
3.51
2.67
3.45
1.95
4.00
3.19
1.69
3.20
3.93
2.20
3.82
Dividends per share
1.53
1.52
1.54
1.65
1.57
1.58
1.73
1.80
1.85
1.84
1.86
1.92
1.99
2.24
2.46
2.61
CAPEX per share
0.45
0.47
0.61
0.69
0.54
0.57
0.65
0.53
0.82
0.46
0.59
0.70
1.01
1.37
1.85
1.76
Book Value per sh.
8.06
8.38
8.78
28.01
17.57
17.93
17.52
17.00
17.14
16.06
14.58
12.73
10.30
10.20
10.01
15.09
Comm.Shares outs.
2,178
2,171
2,136
2,109
3,095
3,041
3,027
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
Avg. annual P/E ratio
18.0
32.0
9.6
4.6
123.7
15.8
19.4
29.4
13.0
33.6
38.2
66.5
25.5
20.2
27.5
14.7
P/E to S&P500
1.0
1.8
0.4
0.1
6.0
1.0
1.3
1.7
0.7
1.7
1.7
2.8
1.0
0.8
0.7
0.5
Avg. annual div. yield
4.2%
3.2%
4.4%
5.9%
4.6%
4.8%
4.4%
4.1%
3.4%
3.4%
3.4%
3.2%
3.3%
2.9%
3.2%
3.4%
Revenue (m)
22,636
24,198
23,850
27,428
45,987
48,047
47,267
44,033
42,237
39,498
39,807
40,122
42,294
46,840
47,994
48,704
Operating margin
16.3%
23.2%
25.5%
14.7%
7.3%
18.7%
20.9%
17.4%
15.8%
19.1%
15.1%
18.2%
21.1%
26.1%
17.7%
27.1%
Depreciation (m)
2,268
1,988
1,631
2,576
7,381
7,427
6,978
6,988
6,691
6,375
5,441
4,637
4,519
3,652
3,625
3,214
Net profit (m)
4,434
3,275
7,808
12,901
861
6,272
6,168
4,404
11,920
4,442
3,920
2,394
6,220
9,843
7,067
13,049
Income tax rate
28.7%
2.8%
20.4%
14.8%
40.6%
12.8%
27.9%
18.5%
30.9%
17.4%
15.4%
62.9%
28.8%
14.7%
19.4%
11.0%
Net profit margin
19.6%
13.5%
32.7%
47.0%
1.9%
13.1%
13.0%
10.0%
28.2%
11.2%
9.8%
6.0%
14.7%
21.0%
14.7%
26.8%
Working capital (m)
2,508
2,787
4,986
12,678
13,423
16,936
16,509
17,817
14,407
10,561
13,410
6,152
3,669
5,263
437
6,394
Long-term debt (m)
5,551
3,916
3,943
16,075
15,482
15,525
16,254
20,539
18,699
23,929
24,274
21,353
19,806
22,736
25,360
30,690
Equity (m)
17,560
18,185
18,758
59,058
54,376
54,517
53,020
49,765
48,647
44,676
40,088
34,336
26,701
25,907
25,317
38,184
ROIC
15.1%
9.7%
25.6%
14.2%
1.5%
8.0%
7.9%
6.0%
15.6%
6.1%
5.8%
3.9%
11.2%
17.1%
12.1%
16.7%
Return on capital
14.8%
7.3%
21.9%
14.3%
2.2%
7.8%
9.0%
6.0%
18.3%
6.0%
5.6%
8.3%
11.5%
14.7%
10.5%
14.6%
Return on equity
25.2%
18.0%
41.6%
21.8%
1.6%
11.5%
11.6%
8.8%
24.5%
9.9%
9.8%
7.0%
23.3%
38.0%
27.9%
34.2%
Plowback ratio
25.1%
(1.0)%
58.0%
73.0%
(463.6)%
23.3%
15.1%
(19.8)%
56.0%
(15.2)%
(30.7)%
(115.8)%
16.8%
42.1%
12.1%
49.3%
Div.&Repurch./FCF
68.4%
64.1%
111.9%
180.1%
70.5%
63.2%
97.0%
116.7%
233.6%
83.5%
97.7%
201.4%
171.7%
105.1%
134.6%
77.1%
Capital Structure
25 Feb · 2022 | Q4
All numbers in millions
Total liabilities
$ 67,437
Total assets
$ 105,694
Long-term debt
$ 30,690
Cash and equiv.
$ 8,096
Goodwill
$ 21,264
Retained earnings
$ 53,696
Common stock
2,527
Enterprise Value
$ 261,921
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
10,450
8,847
8,096
Receivables
6,778
7,851
9,230
Inventory
5,978
6,310
5,953
Other
4,277
3,142
5,407
Current assets
27,483
27,764
30,266
Acc. Payable
3,738
4,594
4,609
Debt due
3,610
6,431
2,412
Other
14,872
16,302
16,851
Current liabilities
22,220
27,327
23,872
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1.48%
5.03%
0.47%
Cash flow
73.48%
32.89%
15.92%
Earnings
84.65%
68.63%
33.68%
Dividends
6.36%
6.42%
2.71%
Book value
50.82%
5.83%
(1.98)%
Insider Trading
Type
Shares
Date
Oosthuizen Johannes Jacobus
Award
21,359
05/04/22
Oosthuizen Johannes Jacobus
Exempt
907
05/04/22
Oosthuizen Johannes Jacobus
InKind
447
05/04/22
Oosthuizen Johannes Jacobus
Exempt
907
05/04/22
Karachun Rita A
Exempt
949
05/04/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2019
10,816
11,760
12,397
11,868
46,841
2020
12,057
10,872
12,551
12,515
47,995
2021
12,080
11,402
13,154
13,521
50,157
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
1.15
1.05
0.75
0.93
3.88
2020
1.27
1.19
1.16
(0.83)
2.79
2021
1.26
0.61
1.81
1.49
5.16
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
0.56
0.58
0.55
0.55
2.24
2020
0.61
0.62
0.61
0.61
2.46
2021
0.65
0.66
0.65
0.65
2.61
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Kenneth Frazier
Full-time employees:
67,000
City:
Kenilworth
Address:
2000 Galloping Hill Rd
IPO:
Jun 15, 1946
Website:
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Recent News
· 14 Mar, 2022 · The Wall Street Journal
· 28 Jan, 2022 · The Wall Street Journal
· 23 Dec, 2021 · The Wall Street Journal
· 26 Nov, 2021 · The Wall Street Journal
· 11 Oct, 2021 · The Wall Street Journal
· 1 Oct, 2021 · The Wall Street Journal
· 30 Sep, 2021 · The Wall Street Journal
· 27 Sep, 2021 · The Wall Street Journal
· 25 Jul, 2021 · The Wall Street Journal
· 24 Mar, 2021 · The Wall Street Journal